KOSDAQBiotech & Pharma348080

Quratis

₩3,555▼ 3.40%2026-11-18 close
Market Cap
₩45.6B
Turnover
₩100M
Volume
30K
Shares out.
12.8M
PER
—
PBR
1.1×
EPS
-₩1,734
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Quratis: Building a CDMO Revenue Base Amid Losses

Quratis has posted losses in each year from 2022 through 2025 and has run five straight loss-making quarters through the third quarter of 2026, so whether its CDMO and adjuvant businesses can build a durable revenue base is the key question.

  1. 1

    Revenue rose to KRW 2.46 billion in 2025, up 557.3% from the prior year, while the operating loss narrowed to KRW 10.3 billion from KRW 19.7 billion in 2024.

  2. 2

    Third-quarter 2026 revenue was KRW 220 million, down 56.6% year on year, and the operating loss was KRW 2.92 billion.

  3. 3

    The cumulative controlling-shareholder net loss for the latest four quarters is KRW 22.2 billion, and total equity at the end of 2025 was KRW 44.3 billion.

  4. 4

    A 9-to-1 free capital reduction resolved in April 2026 will cut paid-in capital from KRW 57.7 billion to KRW 6.4 billion, with KRW 51.3 billion used to offset accumulated deficits.

  5. 5

    Whether the Inventage Lab CDMO contracts and adjuvant supply agreements turn into a stable revenue base, and whether operating losses keep narrowing, are the next points to check.

02

Business structure

Quratis is a vaccine developer that handles the full process from candidate discovery to commercialization on the basis of its vaccine platform technology. The company listed on KOSDAQ in June 2023 and operates a bioplant and research facility in Osong, Chungbuk, with cGMP, EU-GMP and KGMP certifications.

The bioplant's liquid and freeze-dried injectable capacity is reported at 50 million vials per year. Its lead pipeline is the tuberculosis preventive vaccine QTP101, followed by the schistosomiasis preventive vaccine QTP105. Sources describe QTP101's clinical stage differently.

One corporate monitoring service places it in multinational Phase 2b/3 trials, while the company's own notice says the pediatric-to-elderly Phase 1 trial has completed vaccination and is in interim analysis. The business has three legs. The first is vaccine development.

The second is adjuvant supply and CDMO work for vaccines, where the company cites a CDMO supply contract signed in December 2025 with the US-based Access to Advanced Health Institute (AAHI), valued at about KRW 10.4 billion, as its first step into global markets.

The third is contract manufacturing of long-acting injectables for its largest shareholder, Inventage Lab. A clinical manufacturing contract with Inventage Lab signed on April 23, 2026 runs through April 22, 2027, and its contract value was excluded from the disclosure at the counterparty's request.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩500M-₩2.2B−425.7%
2025Q4₩300M-₩2.2B−834.1%
2026Q1₩9,469,179-₩2.5B−25919.9%
2026Q2₩300M-₩3B−939.2%
2026Q3₩200M-₩2.9B−1328.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩8.4B-₩22.4B-₩36.3B−266.4%—−350.0%
2023₩1B-₩16.9B-₩17B−1643.8%−47.0%86.0%
2024₩400M-₩19.7B-₩26.3B−5275.4%−128.3%127.8%
2025₩2.5B-₩10.3B-₩29.7B−420.6%−67.0%23.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 8.41 billion in 2022, the largest year in the 2022–2025 period, and KRW 374 million in 2024, the smallest. Revenue fell 87.8% to KRW 1.03 billion in 2023 and then dropped a further 63.7% to KRW 374 million in 2024. It recovered to KRW 2.46 billion in 2025, up 557.3% from the prior year.

The company attributed the 2025 revenue increase to expansion of its global vaccine and CDMO businesses, and the narrower loss to cost reductions from bioplant operating efficiencies. The operating loss was KRW 22.4 billion in 2022, KRW 16.9 billion in 2023, KRW 19.7 billion in 2024 and KRW 10.3 billion in 2025.

The loss widened again in 2024, so the trend has not been a straight line. Operating margin was -266.4% in 2022, -1,643.8% in 2023, -5,275.4% in 2024 and -420.6% in 2025. When revenue is this small, percentage margins swing sharply, so absolute loss amounts are the more useful gauge.

Net loss attributable to controlling shareholders was KRW 36.3 billion in 2022, KRW 17 billion in 2023, KRW 26.3 billion in 2024 and KRW 29.7 billion in 2025. In 2025 the operating loss narrowed from 2024, yet the controlling-shareholder net loss widened to KRW 29.7 billion.

In the fourth quarter of 2025 the controlling-shareholder net loss reached KRW 12.3 billion against an operating loss of KRW 2.17 billion, a gap of more than KRW 10 billion that points to large non-operating items.

Quarterly revenue was KRW 9.47 million in the first quarter of 2026, KRW 320 million in the second and KRW 220 million in the third, a wide swing. The operating loss of KRW 3.01 billion in the second quarter of 2026 was the largest of the last five quarters, easing to KRW 2.92 billion in the third.

Total equity was KRW 44.3 billion at the end of 2025, and the debt ratio fell from 127.8% in 2024 to 23.7% in 2025.

05

Industry analysis

Tuberculosis vaccines remain an infectious-disease area where effective prevention tools are still limited, which keeps demand interest high. The company says Asian pharmaceutical companies have shown strong interest in tuberculosis vaccines for older adults.

It also says it has discussed vaccine procurement policy with the World Health Organization and international vaccine access bodies.

In adjuvant raw materials, cost competitiveness for global-scale supply matters, and the company is discussing with raw-material partners a switch of its key input squalene to an alternative. Global pharmaceutical companies are also developing TB vaccines, so there are gaps in financial capacity and clinical speed.

Rather than trying to match such large players head-on, Quratis is positioning itself as an adjuvant supply partner tied to global vaccine programs supported by the US NIH. In CDMO, production facilities for vaccines and injectables are the core assets.

Quratis's bioplant has liquid and freeze-dried injectable capacity, which supports the long-acting injectable line that Inventage Lab is building. Much of the CDMO pipeline is still in negotiation or clinical stages, so the order flow remains at an early phase.

06

Outlook

The company set a target of generating meaningful revenue and reaching breakeven in 2026. Its outlook rests on three areas: the Inventage Lab CDMO work, adjuvant supply and the expansion of QTP101 trials.

In an April 2026 notice, the company said it would proceed with additional contract manufacturing agreements for the long-acting injectables IVL3003 and IVL3021. Inventage Lab has reportedly earmarked KRW 13 billion for GMP equipment investment.

In adjuvants, the company says it is negotiating contracts with more than 20 institutions. On clinical development, the plan for QTP101 is a Phase 2b efficacy trial in South Africa, followed by Phase 3 and global commercial supply.

The company also says it is negotiating contracts for QTP101 therapeutic vaccine trials in Africa and the United States. On funding, the company says it holds about KRW 14 billion in operating funds, enough for more than two years of stable operations.

Against that, some observers note that equipment upkeep and clinical costs will keep requiring cash, so the pace of revenue growth matters. The clinical manufacturing agreement with Inventage Lab runs to April 22, 2027, so whether and on what terms it is extended is the next point to check.

07

Valuation

PER
—
PBR
1.1×
ROE
-73.5%
EPS
-₩1,734
BPS
₩3,447
Dividend per share
₩0

The price-to-earnings ratio is not calculated because net losses over the latest four quarters leave no positive earnings base, so comparisons rely more on net assets and operating indicators.

The price-to-book ratio sits slightly above net asset value, measured against total equity of KRW 44.3 billion at the end of 2025. Market capitalization has been moving in a range close to that year-end equity figure, so net assets are the reference point for the price. Dividend payouts are effectively absent.

After the reverse split and new share listing in July 2026, the number of shares outstanding fell from about 115.4 million to about 12.8 million, so pre- and post-reduction share prices are not directly comparable.

In terms of trading, the stock was designated a one-day investment caution stock on August 7, 2026, after its closing price rose more than 60% over five trading days.

Many listed biopharma peers are valued on earnings multiples, but Quratis is loss-making, so comparison rests more on capital and cash than on earnings-based multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Inventage Lab-linked CDMO revenue base

Revenue rose 557.3% to KRW 2.46 billion in 2025, which the company attributes to wider global vaccine and CDMO activity. Inventage Lab has reportedly earmarked KRW 13 billion for injectable production equipment, and Quratis's dedicated GMP line is in trial operation.

The clinical manufacturing agreement signed in April 2026 runs through April 2027, giving some continuity to contract revenue.

Adjuvant CDMO and US program links

The company said it signed a CDMO supply contract with the US-based AAHI in December 2025, valued at about KRW 10.4 billion. The contract is part of a global vaccine development program supported by the US National Institutes of Health.

The company also says it received a cGMP inspection certificate from DAIDS, a unit of NIH, and is negotiating with more than 20 institutions.

Vaccine clinical progress

The company says the Phase 1 trial of QTP101 in older adults has completed enrollment and vaccination and is in interim analysis. It has presented a plan to extend into a Phase 2b efficacy trial in places such as South Africa.

One corporate monitoring source describes QTP101 as in multinational Phase 2b/3 trials, so the stage descriptions differ by source.

09

Bear factors

Persistent operating and net losses

The 2025 operating loss was KRW 10.3 billion and the controlling-shareholder net loss was KRW 29.7 billion. The controlling-shareholder net loss for the latest four quarters totals KRW 22.2 billion.

The operating loss of KRW 3.01 billion in the second quarter of 2026 was the largest of the last five quarters, while quarterly revenue ranged from KRW 9.47 million to KRW 320 million, showing little stability.

Accumulated deficits and the pre-tax loss rule

Press reports put accumulated deficits at about KRW 239.6 billion at the end of 2025. The company carried out a KRW 10 billion third-party rights offering in March 2026, but deficits remain large relative to paid-in capital.

Under the pre-tax loss rule, a company can be designated as a managed-issue stock if the pre-tax loss exceeds 50% of equity two or more times within three years.

Dependence on the largest shareholder and funding

Inventage Lab is the largest shareholder of Quratis with a 40.87% stake and has invested about KRW 35 billion in total. The April 2026 manufacturing agreement is a transaction with the largest shareholder, and its contract value was excluded from the disclosure.

Press coverage notes that if the subsidiary's monetization is delayed, cost burdens could pass through to the parent.

10

Risk factors

Financial and funding

The 9-to-1 free capital reduction resolved in April 2026 is aimed at reducing accumulated deficits. The company says its roughly KRW 14 billion of operating funds supports more than two years of operations, but analysts note that equipment upkeep and clinical costs continue. If new capital is needed later, dilution risk remains.

Related-party dependence and governance

Inventage Lab is both the largest shareholder and a principal CDMO counterparty, so the independence of the transaction structure could become a focus. Because the contract values are undisclosed, the related-party share of revenue cannot be gauged from outside.

Quratis accounts for a large share of Inventage Lab's consolidated assets, so its results can affect the parent's financials.

Market and listing requirements

The August 7, 2026 designation as an investment caution stock followed a rise of more than 60% over five trading days. High price volatility can distort prices through short-term trading concentration.

Because the pre-tax loss rule could lead to managed-issue designation, the pace of loss reduction is directly tied to listing conditions.

11

What to watch next

  1. December 2026

    The company says it has been invited to a global stakeholder summit convened by the WHO and co-hosted by the Indian government. It is a checkpoint for whether adjuvant and TB vaccine supply talks turn into signed contracts.

  2. Around mid-February 2027

    This is when the preliminary 2026 fiscal-year revenue and profit disclosure is expected. The 2025 fiscal-year figures were disclosed in the same format on February 12, 2026. The baselines are KRW 10.3 billion operating loss and KRW 2.46 billion revenue.

  3. Late March 2027

    This is the filing deadline for the 2026 annual business report. Full-year operating loss, controlling-shareholder net loss and changes from total equity of KRW 44.3 billion can be checked against the 2025 baseline.

  4. April 22, 2027

    The clinical manufacturing agreement with Inventage Lab ends on this date. Whether it is extended, and on what terms, is a key test of revenue continuity.

  5. Around May 15, 2027

    This is the filing deadline for the first-quarter 2027 report. It shows whether quarterly revenue, which has ranged between KRW 9.47 million and KRW 320 million, keeps swinging and how far the operating loss falls from KRW 3.01 billion.

12

Overall view

Quratis posted losses in each year from 2022 through 2025 and has run five straight loss-making quarters through the third quarter of 2026. Revenue rose to KRW 2.46 billion in 2025 and the operating loss narrowed to KRW 10.3 billion, but the controlling-shareholder net loss widened to KRW 29.7 billion.

Supportive factors include the Inventage Lab-linked CDMO contracts, the adjuvant supply deal with AAHI in the United States, and progress in QTP101 trials.

Negative factors include large swings in quarterly revenue, a KRW 22.2 billion controlling-shareholder net loss over the latest four quarters, accumulated deficits and the pre-tax loss rule, and a transaction structure dependent on the largest shareholder.

The reduction of capital and the rights offering have addressed the balance sheet, but it is too early to judge whether revenue is building steadily. The next points to check are the preliminary 2026 full-year results, the 2026 annual business report, and the terms after the Inventage Lab agreement ends in April 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. digitaltoday.co.kr
  2. comp.wisereport.co.kr
  3. theinvest.co.kr
  4. pharm.edaily.co.kr
  5. quratis.com
  6. dealsite.co.kr
  7. press9.kr
  8. m.healthcaren.com
  9. quratis.com
  10. dailyinvest.kr
  11. news.nate.com
  12. m.news.nate.com
  13. news.nate.com
  14. m.news.nate.com
  15. digitaltoday.co.kr
  16. m.news.nate.com
  17. topstarnews.net
  18. markets.hankyung.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis